JL1109ES - JL1109ES: Efficacy, safety and patient-reported outcomes (PROs) from the Phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence follow

Full author listing

Ann-Lii Cheng, MD, PhD,1 Minshan Chen, MD, PhD,2 Pierce Chow, MBBS, PhD,3 Ahmed Kaseb, MD,4 Han Chu Lee, MD, PhD,5 Adam Yopp, MD,6 Lars Becker, MD,7 Sairy Hernandez, PhD,8 Bruno Kovic, PhD,9 Qinshu Lian, PhD,8 Ning Ma, MD,8 Chun Wu, PharmD,10 Shukui Qin, MD,11 Masatoshi Kudo, MD, PhD12

¹National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan, ²Sun Yat-sen University Cancer Center, Guangdong Province, China, ³National Cancer Centre Singapore, Singapore and Duke-NUS Medical School Singapore, Singapore ⁴MD Anderson Cancer Center, Houston, TX, ⁵Asan Medical Center, University of Ulsan, Seoul, Republic of Korea; ⁶UT Southwestern Medical Center, Dallas, TX, ⁷F. Hoffmann-La Roche, Basel, Switzerland, ⁸Genentech, Inc., South San Francisco, CA, ⁹Hoffmann-La Roche Limited, Mississauga, ON, Canada, ¹⁰Roche (China) Holding Ltd., Shanghai, China, ¹¹Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing, China, ¹²Kindai University, Osaka, Japan